Regeneron Therapeutic Summary Scorecard
Note: While the therapeutic Casivirimab & imdevimab was developed with the support of Roche, this scorecard evaluates only Regeneron's practices.
A: Commitments and Accountability | Score | C: International cooperation | Score |
A1 The company publishes a global access plan for its product | ![]() | C1 The company commits to C-TAP or MPP | ![]() |
A2 The company commits to comply with human rights standards in relation to product development and marketing | ![]() | C2 The company commits to not enforcing the exclusive rights of Covid-19 related patents | ![]() |
C3 The company supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator | ![]() |
||
C4 The company agrees to license its Covid-19 medical products to other companies | ![]() |
||
E: Equality, non-discrimination & equity | Score | T: Transparency | Score |
E1 The company makes the active ingredient available on reasonable ground. [Only for therapeutics] | ![]() | T1 The company publishes its R&D costs. | ![]() |
E2 The company commits to full technology transfer to other manufacturers | ![]() | T2 The company publishes its profit margin. | ![]() |
E3 The company commits to non-profit, ‘fair’, or differential pricing | ![]() | T3 The company publishes the average and/or marginal costs of production. | ![]() |
E4 The company equitably distributes supplies globally. [Only applies to vaccines] | T4 The company publishes its production capacity. | ![]() |
|
E5 The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable] | ![]() | T5 The company publishes the public subsidies it received during product development and/or testing. | ![]() |
E6 The company agrees to waive exclusive rights in regulatory test data [where applicable]. | ![]() | T6 The company publishes the text of licensing agreements. | ![]() |
T7 The company registers its clinical trials in public repositories. | ![]() |
Regeneron Therapeutic Detailed Evaluation
Explore the results of PAF’s research into Regeneron’s behaviour. Each section is given an overall score; individual criteria are also scored (see icon following the criteria heading). Click on the ‘+’ sign next to each entry to expand and learn more.
A: Commitments and Accountability
Overall score:
A1 The company publishes a global access plan for its product
- Collaborating with Roche to increase global supply of REGEN-COV: “The companies share a commitment to making the antibody cocktail available to COVID-19 patients around the globe and will support access in low- and lower-middle-income countries through drug donations to be made in partnership with public health organizations.”
- No concrete access plans
- Score:
A2 The company commits to comply with human rights standards in relation to product development and marketing
- Regeneron has published a statement on human rights, but does not endorse the UNGPs.
- Score:
C: International Cooperation
Overall score:
C1 The company commits to C-TAP or MPP
- No
- Score:
C2 The company commits to not enforcing the exclusive rights of Covid-19 related patents
- No commitment not to enforce patents
- Score:
C3 The company supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator
- No
- Score:
C4 The company agrees to license its Covid-19 medical products to other companies
- Yes, licensing agreements with Roche (full licensing) and Chugai (development and commercialization)
- Score:
E: Equality, non-discrimination & equity
Overall score:
E1 The company makes the active ingredient available on reasonable ground
- No evidence of sharing API
- Score:
E2 The company commits to full technology transfer to other manufacturers
Regeneron is collaborating with Roche, and does technology transfer to them
The deal with Chugai involves ‘development and commercialization rights’ and thus a limited form of technology transfer
- Score:
E3 The company commits to non-profit or ‘fair’ pricing
- No commitment to non-profit or ‘fair’ pricing is known.
- Score:
E4 The company equitably distributes supplies globally. [Only applies to vaccines]
[Only applies to vaccines]
E5 The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable]
- No information.
- Score:
E6 The company agrees to waive exclusive rights in regulatory test data [where applicable]
- No information.
- Score:
T: Transparency
Overall score:
T1 The company publishes its R&D costs
- R&D costs for 2021 published, but not specific to REGN-COV2
- Score:
T2 The company publishes its profit margin
- 2.30 billion USD in REGN-COV2 sales in Q4 2021, but doesn’t mention a margin
- Score:
T3 The company publishes the average and/or marginal costs of production
- Does not publish the average and/or marginal costs of producing REGN-COV2.
- Score:
T4 The company publishes its production capacity
- Announced in August that by collaborating with Roche, the global supply of REGN-COV2 will become 3,5 times higher. In an earlier press release, the production capacity for treatment doses was estimated to be between 70.000 and 300.000 and the estimated production capacity for prevention doses between 420.000 and 1.300.000.
- Score:
T5 The company publishes the public subsidies it received during product development and/or testing
- ‘The development and manufacturing of REGEN-COV have been funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS’s Office of the Assistant Secretary for Preparedness and Response, under OT number: HHSO100201700020C’
- Score:
T6 The company publishes the text of licensing agreements
- Not found in publicly available databases.
- Score:
T7 The company registers its clinical trials in public repositories
- Registers clinical trials plus results in public clinical trial databases
- Score: